Overview

Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD)

Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
To test a new agent, LBH589, in combination with glucocorticoids as initial therapy of acute graft versus host disease (GVHD).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Collaborator:
Novartis
Treatments:
Glucocorticoids
Histone Deacetylase Inhibitors
Panobinostat